Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus

详细信息    查看全文

• 作者：Wan-Long Chuang ; Rong-Nan Chien ; Cheng-Yuan Peng ; Ting-Tsung Chang ; Gin-Ho Lo ; I-Shyan Sheen ; Horng-Yuan Wang ; Jyh-Jou Chen ; Jenny C. Yang ; Steven J. Knox ; Bing Gao ; Kimberly L. Garrison ; Hongmei Mo ; Phillip S. Pang ; Yu-Chun Hsu ; Tsung-Hui Hu ; Chi-Jen Chu and Jia-Horng Kao
• 刊名：Journal of Gastroenterology and Hepatology
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：31
• 期：7
• 页码：1323-1329
• 全文大小：313K
• ISSN：1440-1746

文摘

Pegylated-interferon-alpha plus ribavirin is the current standard-of-care regimen for treating chronic hepatitis C virus (HCV) infection in Taiwan; however, interferon-based regimens can be poorly tolerated. The interferon-free, two-drug, fixed-dose combination tablet ledipasvir/sofosbuvir is approved in Europe, the USA, and Japan for treating chronic genotype 1 HCV infection. Little is known about its efficacy/safety in Taiwanese patients.